AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01183481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy
Description: Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
Study NCT01183481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
Study NCT01041001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cartistem
Description: allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
Study NCT01041001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture treatment
Study NCT02458287 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bococizumab 75mg placebo
Description: Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Study NCT00384644 — intervention group
Intervention type: DEVICE
Intervention: NiRS measurment of tissue oxygenation
Description: NiRS measurment of tissue oxygenation
Study NCT04264494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP intra articular injection
Description: Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
Study NCT04264494 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NACL intra articular injection
Description: and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
Study NCT02763267 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: 75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
Study NCT01095939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Study NCT01095939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril hydrochloride
Description: Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Study NCT00442130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562 vaccine
Description: The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
Study NCT00442130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
Study NCT02364661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Over night starvation (fasting)
Description: HBV viral load will be analyzed after over-night starvation versus following a morning meal
Study NCT01736930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension
Description: The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
Study NCT01100762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electric Stimulation (CES)
Description: We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
Study NCT01100762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
Study NCT01100762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES and Treadmill
Description: Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
Study NCT01737138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSD
Description: Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
Study NCT01737138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medicine
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
Study NCT03408886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin is administered to reduce pathogenic bacteria.
Study NCT03408886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
Study NCT03408886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MoviPrep
Description: MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
Study NCT03408886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full Spectrum Microbiota
Description: Gut bacteria from healthy human donors are administered orally in a pill form
Study NCT03408886 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Full Spectrum Microbiota
Description: Gut bacteria from healthy human donors are administered orally in a pill form
Study NCT01637090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded.
Study NCT00384449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
Study NCT03019172 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
Study NCT03019172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sachet with cranberry + placebo
Description: Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
Study NCT02389218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single ablation (CryoBalloonAblation (CBA)
Description: Cryoablation at entry, after randomization to this group
Study NCT02389218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential drug adjustment (propafenone, sotalol or flecainide)
Description: Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
Study NCT01518140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Delivery Devices
Description: Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask.
Study NCT01518140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
Study NCT01992328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin
Description: 6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
Study NCT03458234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16 French Foley Catheter
Description: A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex.
Study NCT02415595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor
Study NCT02415595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Description: EFV
Study NCT02415595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: TDF/FTC
Study NCT02415595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC
Description: TDF/FTC
Study NCT04553978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Study NCT02583464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
Study NCT03023319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 100mg daily for 4 cycles (21 days per cycle)
Study NCT03023319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 every 21 days for 4 cycles
Study NCT04168151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung recruitment protocol
Description: lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
Study NCT01686347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ropivacaine
Study NCT02701244 — intervention group
Intervention type: RADIATION
Intervention: Permanent Breast Seed Implant (PBSI)
Description: Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
Study NCT03944564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
Study NCT03944564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static standing
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
Study NCT03944564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic standing
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
Study NCT00814021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT02148536 — intervention group
Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Study NCT03969745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Restrict energy intake window to between 8am and 4pm
Study NCT03969745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
Study NCT01919073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Treatment Group
Description: •The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
Study NCT01919073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Treatment Group
Description: •The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
Study NCT04072952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
Study NCT04072952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 in combination with palbociclib (IBRANCE®)
Description: Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
Study NCT04852549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor exercise
Description: 1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions.
Study NCT02096250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Study NCT02096250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Study NCT02096250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA + ferrous fumarate
Study NCT01601756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated revision knee arthroplasty
Description: revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
Study NCT01601756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional revision knee arthroplasty
Description: revision knee arthroplasty using conventional instruments
Study NCT01504516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil Hydrochloride Tablets 10 mg
Study NCT01395966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: Ear drops
Study NCT01504516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 10 mg Tablets
Study NCT03870373 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
Study NCT01781806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200mg/tenofovir 300mg
Description: The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
Study NCT03528122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recurrent opened macular hole
Description: pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
Study NCT03815630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 and dc-cik cells
Description: Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
Study NCT01026090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)
Study NCT01026090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)
Study NCT01026090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for dronedarone)
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)